There is provided a novel salicylic acid derivative of formula (I), wherein R means hydrogen or a C1-4alkyl group

The invention relates to the novel polymorph modification "E" of N-cyano-N'-methyl-N''{2-[(5-methyl-imidazol-4-yl)-methylthio]-ethyl}-g uanidine (cimetidine "E") characterized by infrared spectroscopical characteristics. According to the process of the invention cimetidine "E" is prepared by accomplishing an aqueous system, which is supersaturated for N-cyano-N'-methyl-N''-{2-[(5-methylimidazol-4-il)-methylthio]-ethyl}-g uanidine at a temperature below 30 DEG C and contains a water-miscible orga...

LA PRESENTE INVENTION EST RELATIVE A UNE NOUVELLE MODIFICATION CRISTALLINE DE LA CIMETIDINE QUI INHIBE LES RECEPTEURS D'HISTAMINE-H-2.

The invention relates to the new monohydrate of N-methyl-N'-{2-[(5-methylimidazol-4-yl)-methylthio]-ethyl}-N''-cyanogu anidine (cimetidine), a histamine-H2 receptor antagonist which is called N-methyl-N'-{2-[(5-methylimidazol-4-yl)-methylthio]-ethyl}-N''-cyanogu anidine H (cimetidine H) as well as to a process for the preparation of same, which comprises pouring a hot, homogeneous aqueous solution of N-methyl-N'-{2-[(5-methylimidazol-4-yl)-methylthio]-ethyl}-N''-cyanogu anidine, optionally conta...

The invention relates to a new crystal modification of N-methyl-N'-{2-[(5-methylimidazol-4-yl)-methylthio]-ethyl}-N''-cyanogu anidine (cimetidine), a histamine H-2 receptor antagonist having the Formula (I) (I) as well as to a process for preparing same. In the description, this new modification is named N-methyl-N'-{2-[(5-methylimidazol-4-yl)-methylthio]-ethyl}-N''-cyanogu anidine Z (cimetidine Z).